Phoenix Children’s Researchers Identify Fibrotic Pericytes and FOXF1 as a Potential Target in Pulmonary Fibrosis
-
By
-
November 16, 2026
-
7 min
Clinical Report: Fibrotic Pericytes and FOXF1 in Pulmonary Fibrosis
Overview
Researchers identified a pericyte population, termed Peri2, in fibrotic but not healthy lungs; these cells showed reduced FOXF1 and increased expression of scar-related genes. In mouse models, pericyte FOXF1 loss worsened fibrosis, while raising FOXF1 reduced scarring and improved measured outcomes, including oxygen levels when increased after injury. The findings are preclinical and do not establish therapeutic benefit in patients.
Background
Pulmonary fibrosis involves progressive scarring and impaired lung function. The supplied article notes that, in children, pulmonary fibrosis most commonly follows lung injury from cancer therapy, particularly hematopoietic cell transplantation. It describes nintedanib, pirfenidone, and nerandomilast as treatments that slow lung-function loss, while stating that none has been shown to restore lung architecture. Prior research has focused largely on alveolar epithelial cells and scar-forming fibroblasts; this study examines pericytes, which support small lung blood vessels.
Data Highlights
| Evidence | Finding |
|---|---|
| Human lung dataset | Single-cell data included 49 donor lungs and 67 lungs from people with pulmonary fibrosis; Peri2 cells and reduced FOXF1 were identified in fibrotic lungs and confirmed with tissue staining. |
| Mouse and laboratory models | Peri2 cells appeared in mice with lung injury. Removing FOXF1 from pericytes worsened fibrosis in bleomycin and silica models and in cultured mouse lung slices. |
| FOXF1 restoration in mice | Raising pericyte FOXF1 reduced fibrosis and improved survival. When raised 8–12 days after injury, it was associated with less lung collagen and microscopic scarring, less weight loss, and better oxygen levels. |
| Human pericyte experiments | Fibroblasts exposed to substances released by human pericytes lacking FOXF1 showed increased movement and multiplication and activation of scar-related genes. |
Key Findings
- Single-cell RNA sequencing identified normal Peri1 pericytes in healthy and diseased lungs and a second population, Peri2, found only in fibrotic lungs.
- Peri2 cells had lower expression of genes marking normal pericytes and higher expression of collagen and other scar-related genes; modeling suggested Peri1 cells may transition to Peri2 as fibrosis develops.
- Peri2 cells and reduced FOXF1 were identified in human pulmonary fibrosis data and confirmed by tissue staining; Peri2 cells were also observed in mice with lung injury.
- Pericyte-specific FOXF1 removal worsened fibrosis across the reported mouse and laboratory models, while increasing FOXF1 reduced fibrosis and improved survival in mice.
- Healthy pericytes release ANGPT1, whereas fibrotic pericytes were reported to release signals that promote fibroblast scarring; restoring ID3 lowered the pro-fibrotic signals IL-8 and CXCL1.
- The authors state that human data show an association between lower FOXF1 and more severe disease; cause-and-effect experiments were conducted in mice and human pericytes grown in the laboratory, not in patients.
Clinical Implications
The study identifies pericyte FOXF1 and its regulated genes as candidate targets for further preclinical investigation, but it does not demonstrate that manipulating this pathway reverses pulmonary fibrosis in patients. The authors identify further work needed, including testing candidate targets in patient lung tissue and additional animal models, developing pericyte-specific delivery, and assessing safety because FOXF1 also functions in other cell types.
Conclusion
The study links a disease-associated pericyte population and reduced FOXF1 with pulmonary fibrosis and reports beneficial effects of FOXF1 restoration in mouse models. Translation to patient treatment remains unproven.
Related Resources & Content
- Gao W, et al.; Nature Communications, year not provided — Study of fibrotic pericytes and FOXF1 in pulmonary fibrosis
- Frontiers in Immunology, 2026 — Identification of potential therapeutic targets for idiopathic pulmonary fibrosis: an integrated multiomics analysis
- ERS/ATS, 2025 — Update of the international multidisciplinary classification of the interstitial pneumonias: an ERS/ATS statement
- MDSpire News — Fibroblast Signals Shape Renal Fibrosis
- the pathologist — Fibroblast Signals Shape Renal Fibrosis
- the pathologist — Biomarker in Fibrotic Lung Disorders Explored in Study
- Update of the international multidisciplinary classification of the interstitial pneumonias: an ERS/ATS statement
- Phase 3 Trials of Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis
- Phase 3 Trials of Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis.
- Comparative efficacy and safety of monotherapy and combination pharmacotherapies for idiopathic pulmonary fibrosis: a network meta-analysis of randomized controlled trials
Based on findings from:
Phoenix Children’s Researchers Identify Fibrotic Pericytes and FOXF1 as a Potential Target in Pulmonary Fibrosis
Phoenix Children's Medical Connection, 2026.
https://www.phoenixchildrensmedconnection.org/news/phoenix-children-s-researchers-identify-fibrotic-pericytes-and-foxf1-as-a-potential-target-in-pulmonary-fibrosis
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.